CCND1 and cancer: Cyclin D1 antagonizes BRCA1-mediated repression of estrogen receptor α (ERα)–dependent gene expression suggesting that silencing of CCND1 combined with PARP inhibitors may lead to substantial benefit for several type of cancer patients [16].